In a move that sent ripples across the Delaware River, pharmaceutical giant Eli Lilly announced Friday that it has selected Pennsylvania’s Lehigh Valley for its newest $3.5 billion manufacturing site.
While the new facility is located in Fogelsville, PA, its proximity to the New Jersey border—just roughly 20 miles from Phillipsburg—marks a significant shift in the regional life sciences landscape. The site will be dedicated to producing the company’s “next-generation” weight-loss medicines, including the highly anticipated investigational drug retatrutide.
For decades, New Jersey has held the crown as the “Medicine Chest of the World,” boasting the highest talent pool concentration in the U.S. However, Friday’s announcement highlights a growing trend of major pharmaceutical investments landing just outside the Garden State’s borders.
The Lehigh Valley was chosen from over 300 applicants, winning out due to its:
-
Location: Immediate access to I-78 and I-476, essential for the logistics of cold-chain injectable medicines.
-
Talent pipeline: Proximity to top-tier STEM universities in both Pennsylvania and New Jersey.
-
Infrastructure: Favorable zoning and ready access to the heavy utilities required for high-tech pharmaceutical manufacturing.
The news comes at a pivotal time for Eli Lilly’s presence in the region. In 2025, the company announced plans to divest its long-standing manufacturing plant in Branchburg, following several years of regulatory scrutiny.
By building a state-of-the-art “Foundry” style facility in Pennsylvania, Lilly is effectively modernizing its regional footprint. The new site will utilize advanced AI, machine learning, and data analytics to ensure a “reliable supply” of its blockbuster metabolic health drugs.
The company says it will hire 850 new high-value permanent jobs and 2,000 construction roles. Those positions will technically be based in Pennsylvania, however, the economic spillover is expected to be felt in Western New Jersey.
-
Commuter synergy: Many of the specialized engineers and lab technicians currently living in New Jersey’s “Pharma Corridor” (counties like Somerset and Hunterdon) are expected to fill these new roles.
-
Supply Chain: New Jersey’s massive logistics and supply chain sector is uniquely positioned to support the transportation of these life-saving injectables.
“Our investment here is about building a shared future with the people and communities of the Commonwealth,” Edgardo Hernandez, president of Lilly Manufacturing Operations said in a release.
Construction is slated to begin later this year, with the facility becoming fully operational in 2031. As Pennsylvania aggressively expands its life sciences incentives, New Jersey policymakers will likely be watching closely to see how the state can maintain its dominance in the face of billion-dollar “next-door” competition.
